Investors

Press Releases

Date Title View
Toggle Summary Tetraphase to Present at 10th Annual Needham Healthcare Conference
Tetraphase to Present at 10th Annual Needham Healthcare Conference Watertown, MA – March 30, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant
View HTML
Toggle Summary Tetraphase to Present at Cowen and Company 31st Annual Health Care Conference
31st Annual Health Care Conference
View HTML
Toggle Summary Tetraphase to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Tetraphase to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference Watertown, MA – February 10, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to
View HTML
Toggle Summary Tetraphase Appoints Patrick Horn, M.D., Ph.D., As Chief Medical Officer
- In New Role, Horn Will Direct Clinical Development of Tetraphase’s Potent Antibiotic Product Portfolio -
View HTML
Toggle Summary Tetraphase Announces Presentation at Lazard Capital Markets and Piper Jaffray & Co. Healthcare Conferences
Tetraphase Announces Presentation at Lazard Capital Markets and Piper Jaffray & Co. Healthcare Conferences Tetraphase Announces Presentation at Lazard Capital Markets and Piper Jaffray & Co. Healthcare Conferences Watertown, MA – November 11, 2010 – Tetraphase Pharmaceuticals, Inc., a
View HTML
Toggle Summary Tetraphase Pharmaceuticals Names Garen Bohlin to Board of Directors to Advance Strategic Interests and Broaden Corporate Development Goals
– Bohlin to provide strategic leadership to optimally leverage the company’s full range of corporate development opportunities –
View HTML
Toggle Summary Tetraphase Announces Presentation at BIO Investor Forum and Panel Discussion at Citi's 5th Annual Biotech Day
Tetraphase Announces Presentation at BIO Investor Forum and Panel Discussion at Citi's 5th Annual Biotech Day Tetraphase Announces Presentation at BIO Investor Forum and Panel Discussion at Citi's 5th Annual Biotech Day Watertown, MA – October 1, 2010 –Tetraphase Pharmaceuticals, Inc.,
View HTML
Toggle Summary Tetraphase to Present at UBS Global Life Sciences Conference
Tetraphase to Present at UBS Global Life Sciences Conference Watertown, MA  –  September 16, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective
View HTML
Toggle Summary Tetraphase Demonstrates that Novel Antibiotic, TP-434, is Effective Against Gram-negative Multidrug-resistant Pathogens in Preclinical Studies
Presentations at 2010 ICAAC Include Data on Company’s Lead Antibiotic, TP-434, and Other Drug Candidates from Ground-breaking Chemistry Platform
View HTML
Toggle Summary Tetraphase Named as One of the FierceBiotech
Tetraphase Named as One of the FierceBiotech Watertown, MA  –  September 15, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug
View HTML